Introduction
Schizophrenia is defined as being treatment resistant if it leads to at least moderate impairment in functioning, and fails to respond to an adequate trial (six weeks with >80% adherence) of two or more antipsychotic drugs at a dose equivalent to at least 600 mg chlorpromazine daily. 1 As many as one-third of patients with schizophrenia experience treatment resistance.
Clozapine is the most effective antipsychotic for reducing positive symptoms and hospitalisations among people with treatment-resistant schizophrenia. [2] [3] [4] It should be used in combination with psychosocial therapies such as cognitive behavioural therapy (CBT) for psychosis, illness self-management training, and family support and education.
Clozapine was introduced in the 1960s but was withdrawn in the 1970s because it caused agranulocytosis. As better drugs for treatmentresistant schizophrenia did not emerge, clozapine was reintroduced with a strict scheme for neutrophil monitoring. Since clozapine was reintroduced in Australia in 1993, its use has steadily increased. 5 Neutrophil monitoring has been so effective at minimising deaths due to agranulocytosis that in 2015 the US Food and Drug Administration recommended weakening the neutrophil cut-off for cessation of treatment to 1 x 10 9 /L (currently 1.5 x 10 9 /L in Australia, with increased monitoring below 2 x 10 9 /L). There have been calls to adopt these relaxed requirements in other countries. 6 However, this should not lead to health professionals underestimating the importance of monitoring and managing adverse effects.
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Cardiovascular
Patients with schizophrenia suffer from higher rates of cardiovascular disease than the general population. This is often aggravated by a higher use of tobacco, poor diet, obesity, a sedentary lifestyle and the use of clozapine itself. 9 Assessment of absolute cardiovascular risk with ongoing monitoring and risk reduction is required. Resources around monitoring 10 and intervening 11 for cardiometabolic health are available.
Blood
The risk of neutropenia and agranulocytosis is greatest in the first four months of therapy. Patients must have weekly full blood counts for the first 18 weeks of treatment and four-weekly full blood counts thereafter. These stringent monitoring requirements have significantly reduced the risk of death for these rare but serious adverse events. Concomitant drugs with significant anticholinergic effects such as oxybutynin, and amitriptyline should be avoided when possible. Preventative aperients should be started at the first sign of constipation. A regular intake of sugar-free fluid should be recommended to all patients especially those prescribed increased dietary fibre. Regular exercise is also recommended. When intestinal obstruction has been excluded, a stimulant and softener combination such as docusate with senna may be used. 12 The literature suggests that stimulant laxatives such as senna are not harmful to the colon, although this does not include studies of patients taking clozapine.
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Metabolic
After starting treatment a weight gain of over 10 kg is common and may continue for a year or longer. Half of the patients taking clozapine will develop metabolic syndrome and type 2 diabetes. 12 Dietary modification and exercise may have significant positive effects on weight if patients can adhere to these regimens.
Metformin is an underused, evidence-based intervention for weight loss that is both safe and effective in patients without glucose intolerance or diabetes. 9 On average there is a 3.1 kg weight loss, 12 but metformin may cause a vitamin B 12 deficiency so B 12 concentrations should be checked.
Dsylipidaemia and hyperglycaemia may occur with or without weight gain. 12 Metformin is the recommended first-line treatment for hyperglycaemia. 12 Patients with dyslipidaemia should be treated in the same way as other patients. Statins should be used for patients who meet the clinical criteria for their prescription.
Fever
Fever, cold and flu-like symptoms due to viral upper respiratory tract infections are common in the community, including in patients taking clozapine. In most cases these symptoms do not require adjustment of therapy. However, because these signs and symptoms may indicate myocarditis or secondary infections due to neutropenia, these conditions should be ruled out. Urgent full blood counts should be ordered.
Sedation
Sedation is a common and troubling adverse effect. Many patients sleep 10-12 hours per night. While shifting doses to night-time may reduce afternoon sedation, it can increase morning tiredness. The dosing schedule should be negotiated with patients. Treatment augmentation with drugs such as aripiprazole may help to reduce the required clozapine dose. This can reduce sedation, but should not be prescribed without consultation with a psychiatrist. 12 
Chest pain, myocarditis and cardiomyopathy
Chest pain requires careful consideration. Simple causes of chest pain such as gastro-oesophageal reflux disease are common in patients taking clozapine, however myocardial infarction, myocarditis and cardiomyopathy should be considered as differential diagnoses.
Myocarditis typically occurs in the first three weeks of therapy while cardiomyopathy occurs later in treatment (median nine months). 12, 13 Although rare (between 1 in 1000 and 1 in 5000) in short-term studies, in one retrospective Australian study of patients treated with clozapine and followed for 11 years, the incidence of cardiomyopathy was 4.65% (6/129). 13 Ceasing clozapine may have catastrophic consequences for some patients and care should be taken not to diagnose myocarditis without clinical investigations.
14,15 A same-day review by an emergency department or cardiologist for ECG, troponin, chest X-ray and possible echocardiogram may be required. Myocarditis or cardiomyopathy should be confirmed by a cardiologist to avoid unnecessary cessation of clozapine.
Tachycardia
Tachycardia is common especially during the first four weeks of clozapine therapy. It is usually benign.
12,13
Postural hypotension
Postural hypotension is common. Regular adequate fluid intake should be advocated, although specific advice to avoid sugary drinks is important. General advice around getting up slowly and leg muscle flexing is appropriate. Alcohol may worsen postural hypotension and the patient's intake should be assessed. In rare cases fludrocortisone may be required. 12 
Gastrointestinal
Nausea is a common and dose-related adverse effect of clozapine. 12 Dyspepsia and reflux may be treated with proton pump inhibitors. Although variations in clozapine concentrations have been reported with omeprazole, [16] [17] [18] all proton pump inhibitors are generally considered to be safe to use in patients taking clozapine.
Constipation
The prevalence of constipation is up to 60%. 19 Severe untreated constipation may cause a fatal bowel obstruction. [20] [21] [22] Red flag signs and symptoms include abdominal pain, distension, vomiting, overflow diarrhoea, absent bowel sounds and signs or symptoms of sepsis.
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Strategies to improve adherence
Multifaceted interventions to improve adherence may include dose administration aids (e.g. Webster-pak), phone alarms, and direct monitoring of medicationtaking by carers. Clozapine coordinators and case managers can help identify non-government organisations that may offer a monitoring service. Individual or group education from clozapine coordinators and pharmacists is also recommended.
Treatment interruptions
Abrupt withdrawal of clozapine should be avoided as it may cause cholinergic rebound and acute psychosis.
Treatment interruptions for more than 48 hours, for example because of non-adherence, require an increase in the frequency of blood tests to weekly (if patients are having monthly blood tests). If the treatment interruption lasts more than 72 hours, re-titration of the clozapine dose is required. Failure to re-titrate causes an unacceptably high risk of seizures, severe hypotension, and coma. 12 The patient's regular clozapine monitoring service and psychiatrist should be contacted.
Therapeutic drug monitoring
Clozapine concentrations are measured in trough samples and most studies show that the threshold for response is 350-600 micrograms/L. 12 Concentrations of the main metabolite, norclozapine, are routinely reported with clozapine concentrations, but its importance for therapeutic efficacy is uncertain.
Hypersalivation
Hypersalivation, particularly while sleeping, is a troublesome adverse effect that may embarrass and stigmatise patients. Sucking sugar-free lozenges may help to remind patients to swallow saliva. Absorbent pillow slips and placing a towel over the pillow at night may also help. Sublingual anticholinergic drugs have also been used to some effect. Drugs that have been tried include:
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• atropine eye drops either used sublingually directly or as a mouthwash (2 drops in 10 mL water)
• hyoscine hydrobromide tablets 300 micrograms sucked or chewed up to three times a day (systemic absorption is possible and may potentially cause or aggravate tachycardia, constipation or confusion)
• ipratropium metered dose inhaler 1-2 sprays up to three times a day sublingually.
Seizures
Clozapine has been associated with seizures with a cumulative one-year risk of approximately 2.9-5%. 25, 26 Seizures include a wide variety of epileptic activity and not just generalised tonic-clonic seizures.
The risk is increased in patients with serum clozapine concentrations greater than 1000 nanograms/mL. 12, [25] [26] [27] [28] Reducing the intake of alcohol may reduce the risk.
Immediate referral to an emergency department is indicated for patients who have a seizure while taking clozapine. Clozapine concentrations, testing for illicit drugs, brain imaging and a neurology review may be required. An accurate diagnosis of seizures is essential before considering stopping clozapine. It may be in the best interests of the patient to continue taking clozapine with the addition of an antiepileptic drug such as sodium valproate or lamotrigine. 12, 27, 28 The patient's psychiatrist should be consulted before any changes.
Nocturnal enuresis
Nocturnal enuresis affects up to one in five patients. 29 Non-drug treatments are first-line and include:
• bladder training (physiotherapists may help with this)
• reducing caffeine intake • reducing night-time fluids (but not total daily fluid intake)
• planned night-time wakening to urinate.
Continence pads and sheet protectors may be used if these methods are ineffective. In resistant cases desmopressin nasal spray (10-20 micrograms at night) may be used under specialist advice, although it is not listed on the PBS for this indication, and hyponatraemia may result. 12, 30 
